Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Un grupo de alto riesgo, doble-hit, de mieloma recién diagnosticado identificado por análisis genómico

    Walker BA (1), Mavrommatis K (2), Wardell CP (1), Ashby TC (1), Bauer M (1), Davies F (1), Rosenthal A (3), Wang H (3), Qu P (3), Hoering A (3), Samur M (4), Towfic F (5), Ortiz M (6), Flynt E (5), Yu Z (5), Yang Z (5), Rozelle D (7), Obenauer J (7), Trotter M (6(, Auclair D (8), Keats J (9), Bolli N (10), Fulciniti M (4), Szalat R (4), Moreau P (11), Durie B (12), Stewart AK (13), Goldschmidt H (14), Raab MS (14,15), Einsele H (16), Sonneveld P (17), San Miguel J (18), Lonial S (19), Jackson GH (20), Anderson KC (4), Avet-Loiseau H (21,22), Munshi N (4), Thakurta A (5), Morgan G (23).

    (1) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
    (2) Celgene Corporation, San Francisco, CA, USA.
    (3) Cancer Research and Biostatistics, Seattle, WA, USA.
    (4) Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (5) Celgene Corporation, Summit, NJ, USA.
    (6) Celgene Institute of Translational Research Europe, Sevilla, Spain.
    (7) Rancho BioSciences, San Diego, CA, USA.
    (8) Multiple Myeloma Research Foundation, Norwalk, CT, USA.
    (9) Translational Genomics Research Institute, Phoenix, AZ, USA.
    (10) University of Milan, Milano, Italy.
    (11) University of Nantes, Nantes, France.
    (12) Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA.
    (13) Department of Hematology, Mayo Clinic, Scottsdale, AZ, USA.
    (14) Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.
    (15) German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany.
    (16) Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany.
    (17) Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    (18) Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (19) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (20) Department of Haematology, Newcastle University, Newcastle, UK.
    (21) Centre de Recherche en Cancérologie de Toulouse Institut National de a Santé et de la Recherche Médicale, U1037, Toulouse, France.
    (22) L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France.
    (23) Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

    Leukemia 02 de JULIO de 2018

  • Un estudio observacional europeo de la administración de terapia endocrina en pacientes con diagnóstico inicial de cáncer de mama avanzado positivo para receptores hormonales

    Bastiaannet E (1), Charman J (2), Johannesen TB (3), Schrodi S (4), Siesling S (5), van Eycken L (6), Walsh PM (7), Audisio RA (8), Boelens PG (1), Rubio IT (9), Jones N (10), Lewis J (10), van de Velde CJH (11).

    (1) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
    (2) National Cancer Registration and Analysis Service, Public Health England, Birmingham, United Kingdom.
    (3) Cancer Registry of Norway, Oslo, Norway.
    (4) Munich Cancer Registry of the Munich Tumour Centre, Institute of Medical Information Processing, Biometry and Epidemiology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany.
    (5) Netherlands Cancer Registry, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
    (6) Belgian Cancer Registry, Brussels, Belgium.
    (7) National Cancer Registry, Cork, Ireland.
    (8) University of Liverpool, St Helens Teaching Hospital, St Helens, United Kingdom.
    (9) Breast Surgical Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
    (10) AstraZeneca, Cambridge, United Kingdom.
    (11) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands

    Clinical Breast Cancer 29 de NOVIEMBRE de 2017

  • Ultrasound characteristics of endometrial cancer as defined by the International Endometrial Tumor Analysis (IETA) consensus nomenclature

    Epstein E (1), Fischerova D (2), Valentin L (3), Testa AC (4), Franchi D (5), Sladkevicius P (3), Filip F (2), Lindqvist PG (6), Mascilini F (4), Fruscio R (7), Haak LA (8), Opolskiene G (9), Pascual MA (10), Alcazar JL (11), Chiappa V (12), Guerriero S (13), Carlson J (14), Van Holsbeke C (15), Leone FPG (16), De Moor B (17), Bourne T (18,19), van Calster B (19), Installe A (17), Timmerman D (19,20), Verbakel JY (19,21), Van den Bosch T (20). (1) Department of Clinical Science and Education, Södersjukhuset and Department of Women's and Children's health Karolinska Institutet, Stockholm, Sweden.
    (2) Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
    (3) Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Lund University, Sweden.
    (4) Department of Gynecological Oncology, Catholic University of Sacred Heart, Rome, Italy.
    (5) Department of Gynecological Oncology, Milan, Italy.
    (6) Department of Obstetrics and Gynecology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
    (7) Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy.
    (8) Institute for the Care of Mother and Child, Prague, Czech Republic and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
    (9) Center of Obstetrics and Gynecology, Vilnius University Hospital, Santariskiu clinic, Lithuania.
    (10) Department of Obstetrics, Gynecology, and Reproduction, Hospital Universitario Dexeus, Barcelona, Spain.
    (11) Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, Pamplona, Spain.
    (12) Department of Obstetrics and Gynecology, National Cancer Institute, Milan, Italy.
    (13) Department of Obstetrics and Gynecology, University of Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy.
    (14) Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
    (15) Department of Obstetrics and Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium.
    (16) Department of Obstetrics and Gynecology, Clinical Sciences Institute, L. Sacco, Milan, Italy.
    (17) Department of Electrical Engineering, ESAT-SCD, STADIUS Center for Dynamical Systems, Signal Processing and Data Analysis, KU Leuven, and imec, Leuven, Belgium.
    (18) Department of Obstetrics and Gynaecology, Queen Charlottes and Chelsea Hospital, Imperial College London, UK.
    (19) Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
    (20) Department of Obstetrics and Gynecology, University Hospital Leuven, Leuven, Belgium.
    (21) Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.

    Ultrasound in Obstetrics & Gynecology 25 de SEPTIEMBRE de 2017

  • Una nueva era para la neuroimagen en Medicina Nuclear en España: ¿De dónde partimos en España?

    Balsa MA (1), Camacho V (2), Garrastachu P (3), García-Solís D (4), Gómez-Río M (5), Rubí S (6), Setoain X (7), Arbizu J (8); por el Grupo de Neuroimagen SEMNIM.
    (1) Servicio de Medicina Nuclear, Hospital Universitario de Getafe, Madrid, España.
    (2) Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau i Universitat Autònoma de Barcelona , Barcelona, España.
    (3) Servicio de Medicina Nuclear, Hospital San Pedro y Centro de Investigación Biomédica de la Rioja (CIBIR), Logroño, España.
    (4) Servicio de Medicina Nuclear, Hospital Universtario Virgen del Rocío, Sevilla, España.
    (5) Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Granada (CHGRA) e Instituto de Investigación Biosanitaria Granada (IBS), Granada, España.
    (6) Servicio de Medicina Nuclear, Hospital Universitari Son Espases e Instituto de Investigación Sanitaria de Palma, Palma, España.
    (7) Servicio de Medicina Nuclear, Hospital Clínic de Barcelona, Barcelona, España.
    (8) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España. 

    Revista Española de Medicina Nuclear e Imagen Molecular 22 de FEBRERO de 2017

  • Utility of flow cytometry studies in the management of patients with multiple myeloma

    Paiva B (1), Merino J, Miguel JF.
    (1) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, Pamplona, Spain. 

    Current Opinion in Oncology 07 de SEPTIEMBRE de 2016

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra